Cargando…
Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab
Bullous pemphigoid (BP) is an autoimmune disorder known to be mediated by immunoglobulin G (IgG) autoantibodies. The role of immunoglobulin E (IgE) antibodies is being investigated as their presence has been described in severe cases. Herein, we report a patient of BP who was refractory to most conv...
Autores principales: | Sinha, Surabhi, Agrawal, Diksha, Sardana, Kabir, Kulhari, Anita, Malhotra, Purnima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413437/ https://www.ncbi.nlm.nih.gov/pubmed/32832453 http://dx.doi.org/10.4103/idoj.IDOJ_438_19 |
Ejemplares similares
-
Diffuse Juvenile Bullous Pemphigoid Managed Successfully With a Short Course of Cyclophosphamide
por: Rani, Seema, et al.
Publicado: (2022) -
Cutaneous Histoplasmosis: An Unusual Presentation with Nasal Obstruction
por: Sinha, Surabhi, et al.
Publicado: (2020) -
Increasing evidence for omalizumab in the treatment of bullous pemphigoid
por: Lonowski, Sarah, et al.
Publicado: (2020) -
Omalizumab as a corticosteroid‐sparing agent in the treatment of bullous pemphigoid
por: Vassallo, Camilla, et al.
Publicado: (2022) -
Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments
por: Bilgiç Temel, Aslı, et al.
Publicado: (2017)